Maze Therapeutics, Inc.

Maze Therapeutics, Inc.

MAZENYSE / NASDAQHealthcareSmall cap

$31.37-$1.06 (-3.3%)

Last close · Data as of Nov 20, 2026

Market cap
$1.4B
P/E
-10.7x
EV / EBITDA
-8.8x
Revenue
$0.00
ROCE
-38.2%

-11.8% over the last year

Maze Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-3.3%
3M
+8.4%
6M
+25.3%
1Y
-11.8%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$1.06 (-3.3%) from $32 to $31 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MAZE, bought on each weekday since 2025.

News & filings

What Maze Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 131 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.

Read moreShow less

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Sector
Healthcare
Shares outstanding
49.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.4B
P/E
-10.7x
P/B
4.0x
EV / EBITDA
-8.8x
52-week high
$51.83
52-week low
$22.39

Profitability

ROE
-36.9%
ROCE
-38.2%
ROIC
-59.7%
ROA
-33.0%

Growth

Revenue
$0.00
Revenue growth, 1Y
-100.0%
Net profit growth, 1Y
-351.0%
Free cash flow
-$112.7M

Solvency

Current ratio
15.50
Debt / Equity
0.07
Debt / Assets
0.06
CFO / Net profit
0.85
Cash / Market cap
13.5%

Revenue and net profit

Revenue fell 100.0% in FY2025; net profit is the dashed line.

Maze Therapeutics, Inc. revenue and net profit by fiscal year
Maze Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$114.9M
FY2023$0.00-$100.4M
FY2024$167.5M$52.2M
FY2025$0.00-$131.1M

Cash flows

FY2025: -$111.9M from operations, -$112.7M free after investment (dashed).

Maze Therapeutics, Inc. operating and free cash flow by fiscal year
Maze Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$99.2M-$101.2M
FY2023-$86.8M-$87.3M
FY2024$76.0M$74.8M
FY2025-$111.9M-$112.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00-100.0%1Y
EBITDA
-$140.5M-330.8%1Y
Net profit
-$131.1M-351.0%1Y
Cash from operations
-$111.9M-247.4%1Y
Free cash flow
-$112.7M-250.7%1Y
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$140.5M-$131.1M-$112.7M-36.9%-100.0%-351.0%

Monthly returns

Month-by-month returns of MAZE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$397.1M
Liabilities$42.2M
Equity$355.0M
Paid-in capital$844.4M
Retained earnings-$489.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MAZE highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): Maze Therapeutics, Inc., MapLight Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Maze Therapeutics, Inc.MAZEthis company$1.4B-10.7x4.0x-36.9%-8.8x
Aveanna Healthcare Holdings Inc.AVAH$1.4B6.4x7.4x115.3%10.3x
Septerna, Inc.SEPN$1.4B-28.9x3.7x-12.8%-16.6x
Healthcare Services Group, Inc.HCSG$1.4B23.8x2.8x11.6%14.9x
AtriCure, Inc.ATRC$1.4B-120.6x2.8x-2.3%79.2x
Precigen, Inc.PGEN$1.4B-5.5x65.8x-1198.6%-5.9x
Integra LifeSciences Holdings CorporationIART$1.4B-2.6x1.3x-49.5%-9.7x
MapLight Therapeutics, Inc.MPLT$1.4B—3.0x-35.2%—
Butterfly Network, Inc.BFLY$1.4B—6.9x-39.3%—
Peer median—-4.1x3.3x-24.0%2.2x

Year-to-date ROI

MAZE since 1 January, against earlier years.

Historical volatility

MAZE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Maze Therapeutics, Inc. operating margin by fiscal year
Maze Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY202434.4%
FY2025—
LineFY2025
Operating expensesOperating Expense$142.9M
Research and developmentResearch And Development$108.5M
Total expensesTotal Expenses$142.9M
Pretax incomePretax Income-$131.1M

Learn while you research

Academy chapters picked for Maze Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →